Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

South Korea · Delayed Price · Currency is KRW

5,950.00

+130.00 (2.23%)

At close: Aug 24, 2026

-5.10% (1Y)

Market Cap	66.21B -7.2%
Revenue (ttm)	82.18B -4.4%
Net Income	6.95B -45.1%
EPS	601.36 -45.1%
Shares Out	11.38M
PE Ratio	9.68
Forward PE	n/a
Dividend	190.00 (3.24%)
Ex-Dividend Date	Dec 29, 2025

Volume	34,657
Open	5,840.00
Previous Close	5,820.00
Day's Range	5,840.00 - 6,050.00
52-Week Range	4,820.00 - 6,820.00
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Sinil Pharmaceutical

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In ... [Read more]

Industry Pharmaceutical Preparations

Founded 1971

Employees 287

Stock Exchange KOSDAQ

Ticker Symbol 012790

Full Company Profile

Financial Performance

In 2025, Sinil Pharmaceutical's revenue was 80.56 billion, a decrease of -9.92% compared to the previous year's 89.44 billion. Earnings were 7.53 billion, a decrease of -47.34%.

Financial Statements